December 24, 2015
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL

TOKYO, Japan, December 24, 2015 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") announced today its submission of a supplemental New Drug Application ("sNDA") to the Pharmaceuticals and Medical Devices Agency ("PMDA") in Japan for TREAKISYM® ("bendamustine") in the treatment of first-line low-grade non-Hodgkin's lymphoma ("Lg-NHL") and mantle cell lymphoma ("MCL"). SymBio received marketing approval for TREAKISYM® on October 27, 2010, to treat Japanese patients with relapsed or refractory Lg-NHL and MCL. TREAKISYM®.

Submission of this sNDA will not impact the Company's financial forecast for FY2015.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

[Glossary]

About Non-Hodgkin's lymphoma

Lymphatic malignancy except for Hodgkin's lymphoma. In Japan, most of lymphomas is Non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma is categorized by Progression speed, which means lymphoma progressing annually is low-grade and monthly is mid and high grade.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus on oncology, hematology and pain management.